No differences have been seen in hemoglobin levels between patients receiving 1. The main side effect from treatment is myelotoxicity. In addition, patients with bone metastases secondary to prostate cancer have a prolonged survival compared with patients at a similar stage with other malignancies such as lung cancer. Campa JA 3rd, Payne R. Currently, there are 3 radionuclides approved for treatment of bone pain, phosphorus, strontium, and samarium, each with differing bone targeting mechanisms.
Radiopharmaceuticals Metastron (Strontium-89) and Samarium-153 (Quadramet) for Metastatic Bone Pain
Samarium (Sm) lexidronam - Wikipedia
Preclinical escalating single 0. The half-life of samarium is 1. Figure 2. Boston, Mass: GK Hall; Subsequently, 16 additional patients were treated at both the 1. Bone Metastasis.
Overview of Samarium Sm 153 Lexidronam in the Treatment of Painful Metastatic Bone Disease
Retreatment with samarium Sm lexidronam has been reported primarily in a setting of an initial favorable palliative response followed by recurrence of symptoms. Efficacy was evaluated by blinded patient evaluations of pain using a visual analog scale VAS and recording of daily opioid analgesic use. Paget S. Galasko CSB.
Serafini AN. The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations. Preclinical escalating single 0. These agents are also helpful for patients previously treated to their maximal normal tissue tolerance with focal external beam radiation who have progressive or recurrent symptoms at the treated sites. Krishnamurthy GT, Krishnamurthy S. You must see it we are young korean movie